Global Rheumatoid Arthritis Competitor Landscape Report 2018: Ongoing Development Activities and Analysis of Current & Potential Future Product Positioning

| Source: Research and Markets Research and Markets

Dublin, Feb. 04, 2019 (GLOBE NEWSWIRE) -- The "Competitor Landscape: Rheumatoid Arthritis" report has been added to ResearchAndMarkets.com's offering.

"Competitor Landscape: Rheumatoid Arthritis", briefings contain evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report

  • If the results of the Phase II MANTA safety trial are required by the FDA prior to filing for regulatory approval of filgotinib for Rheumatoid Arthritis (RA), this could delay US approval by 2 years.
  • Given that the Phase II NCT03241108 trial is limited to 90 patients in the EU, it is likely that NovImmune will need to initiate a second Phase II trial with a larger number of patients, including US patients, prior to proceeding with a Phase III program for NI-0101 in Rheumatoid Arthritis (RA).
  • The Phase II trial assessing the immunogenicity and safety of Zostavax in Rheumatoid Arthritis (RA) patients using abatacept, if positive, is likely to boost physician opinion of abatacept's safety profile in Rheumatoid Arthritis (RA), and reduce potential physician concerns that the use of abatacept may negatively impact the effectiveness of some immunizations, as suggested by its US FDA label.

Landscape Updates

  • Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product's lifecycle management initiatives.
  • Market Entry' & Direction of Travel' positioning analysis for pipeline & currently approved therapies.

Pipeline Landscape

  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2019.

Approved Product Landscape

  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2019.

Appendix

  • Current early stage RA pipeline & candidate Watch List',
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

  • The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • Market Entry' & Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Key Topics Covered:

  1. Introduction to Sociable Pharma's Competitor Landscape'
  2. Executive Summary
  3. Key Events & Landscape Updates
  4. Landscape Updates
  5. Order of Entry
  6. Key Competitor Market Entry Strategies
  7. Lifecycle Development
  8. Key Competitor Direction of Travel'
  9. Pipeline Landscape
  10. Pipeline Summary
  11. Approved Product Development Landscape
  12. Lifecycle Development
  13. Appendix

Companies Mentioned

  • AbbVie
  • Abivax
  • Ablynx
  • ACEA Biosciences
  • Acerta Pharma
  • Akari Therapeutics
  • Akros Pharma
  • Amgen
  • Asana Biosciences
  • Astellas
  • AstraZeneca
  • Bayer
  • Biocad
  • Bird Rock Bio
  • BMS
  • Boehringer Ingelheim
  • Can-Fite Biopharma
  • Celgene
  • Chemo-Centryx
  • Cyclacel
  • Daichii Sankyo
  • Eddingpharm
  • Eisai
  • Galapagos
  • Genentech
  • Gilead
  • GSK
  • Hanmi
  • Hutchison Medi Pharma
  • Innate Pharma
  • Innocare Pharma
  • Istesso
  • Janssen
  • Japan Tobacco
  • Jiangsu HengRui
  • Lilly
  • Lupin
  • MacroGenics
  • MedImmune
  • Merck KGaA
  • Mesoblast
  • Momenta
  • MorphoSys
  • Morphotek
  • MSD
  • Nektar Therapeutics
  • Novartis
  • NovImmune
  • Noxopharm
  • Nuevolution
  • Oscotec
  • OSE Immuno Therapeutics
  • Pfizer
  • Philogen
  • Principia Biopharma
  • Protalex
  • Reata Pharmaceuticals
  • Regen BioPharma
  • Regeneron
  • Rigel Pharmaceuticals
  • Roche
  • Rottapharm Biotech
  • R-Pharm
  • Sanofi
  • Sareum
  • Swedish Orphan Biovitrum
  • Taiho
  • Taisho
  • Takeda
  • TiGenix
  • UCB
  • Valeant
  • Viela Bio
  • Vitaeris
  • WuXi
  • Xencor

For more information about this report visit https://www.researchandmarkets.com/research/zxxq85/global_rheumatoid?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. 


            











    

        

        
Contact Data